BioLife Solutions 的空头股数下降，尽管高管股票出售，但仍维持“买入”评级。 BioLife Solutions sees short interest drop, maintains "Buy" rating despite executive stock sales.

11月,生物生命解决方案的低利率下降23.4%,分析师的“Buy”评级维持不变,平均价格目标为27.50美元。 BioLife Solutions saw a 23.4% drop in short interest in November, with analysts maintaining a "Buy" rating and a $27.50 average price target. 该公司开发了细胞和基因治疗的生物生产工具,最近管理人员出售了股票,增加了机构所有权。 The company, which develops bioproduction tools for cell and gene therapy, has seen recent stock sales by executives and increased institutional ownership. 股票最近交易额为27.47美元,市场上限为12.7亿美元。 The stock traded at $27.47 recently, with a market cap of $1.27 billion.